Vascular benefits of angiotensin receptor blockers (Q36861584)

16 August 2017

1 reference

title

Vascular benefits of angiotensin receptor blockers (English)

1 reference

16 August 2017

Adriaan A Voors

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

987-997

1 reference

Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Effects of losartan and enalapril on small artery structure in hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Valsartan improves fibrinolytic balance in atherosclerotic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin receptor blockers and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin receptor blockers and risk of myocardial infarction: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Bradykinin B2 receptor antagonism: a new direction for acute stroke therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Bradykinin mediates the acute effect of an angiotensin-converting enzyme inhibitor on cerebral autoregulation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

A preliminary report on the application of noscapine in the treatment of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.987

10.1517/13543784.16.7.987

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference